Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Pricing and Reimbursement in the US - Introduction | 7 | 2 |
| GBI Research Report Guidance | 8 | 1 |
| Healthcare System in the US - Overview | 9 | 19 |
| Healthcare Expenditure | 9 | 1 |
| Healthcare Expenditure and GDP | 9 | 2 |
| Healthcare Expenditure The US versus Top Five Countries of Europe | 11 | 2 |
| Healthcare Expenditure by Category | 13 | 1 |
| Type of Healthcare Expenditure in the US | 13 | 2 |
| National Healthcare Expenditure Public, Private, Out-of-Pocket | 15 | 3 |
| National Healthcare Expenditure Type of Sponsor | 18 | 1 |
| Healthcare Infrastructure | 19 | 1 |
| Hospitals | 19 | 1 |
| Hospital Beds | 20 | 1 |
| Healthcare Professionals | 20 | 1 |
| Health Insurance | 21 | 1 |
| Health Insurance Coverage | 21 | 1 |
| Health Insurance Providers | 22 | 1 |
| Public Health Insurance | 22 | 1 |
| Private Health Insurance | 23 | 3 |
| Demographic Trends Affecting Healthcare | 26 | 1 |
| Population Demography | 26 | 2 |
| Pharmaceutical Regulations in the US - Overview | 28 | 5 |
| Pharmaceutical Industry in the US | 28 | 1 |
| PEST Analysis | 28 | 1 |
| Political | 28 | 1 |
| Economical | 28 | 1 |
| Social | 29 | 1 |
| Technological | 29 | 1 |
| Healthcare Regulation | 30 | 1 |
| Highlights of the Budget 2011-2012 | 31 | 2 |
| Pricing of Pharmaceutical Drugs in the US | 33 | 11 |
| Pricing Overview | 33 | 1 |
| Regulatory Bodies | 34 | 1 |
| Pricing Control | 34 | 1 |
| 340B Drug Pricing Program | 35 | 1 |
| Key Trends | 35 | 1 |
| Brand Name Drug Prices Increase in the Face of Generic Competition | 35 | 1 |
| Significant Decrease in Average Price of Generic Drugs | 36 | 1 |
| PPACA Introduced by the US President to Tackle Soaring Prescription Drug Prices | 37 | 2 |
| Generic Price War at Retail Sector | 39 | 1 |
| Major Challenges | 40 | 1 |
| Reducing Wastage in Healthcare Spending | 40 | 1 |
| Government s Cost Rationalization Efforts will make Future Tough for Big Pharmaceutical Companies | 40 | 1 |
| Medicaid Pricing for Dual Eligibles of Medicare Part - D | 41 | 1 |
| New ICD-10 (International Classification of Diseases) Coding System | 41 | 2 |
| Medicare Part B Drug Pricing Does Not Reflect Market Price Accurately | 43 | 1 |
| Reimbursement of Pharmaceutical Drugs in the US | 44 | 20 |
| Regulatory Bodies | 45 | 1 |
| Prescription Drugs | 45 | 1 |
| Biologics | 46 | 1 |
| Preferred Drug List (PDL) | 47 | 1 |
| Regulating Agency | 47 | 1 |
| Coverage of Drugs under PDL | 47 | 1 |
| Reimbursement by Health Insurance Companies | 48 | 1 |
| UnitedHealth Group | 49 | 1 |
| WellPoint, Inc. | 49 | 1 |
| Kaiser Foundation Group | 49 | 1 |
| Humana Group | 50 | 1 |
| Aetna Group | 50 | 1 |
| Pharmacy Benefit Managers (PBMs) | 51 | 1 |
| Reimbursement Programs in the US | 52 | 1 |
| Case Studies | 53 | 1 |
| Washington Prescription Drug Program | 53 | 1 |
| New Mexico Discount Prescription Drug Program | 53 | 1 |
| Discount Programs in Other States | 54 | 1 |
| Key Trends | 55 | 1 |
| Rebate Reforms and Healthcare Cuts to Reduce Federal Deficit | 55 | 2 |
| Medicare Part D Changes in Standard Benefit Parameters | 57 | 2 |
| Reimbursement of Brand Name Drugs | 59 | 1 |
| Reimbursement of Generic Drugs | 60 | 1 |
| CMS Finalizes Medicare Hospital Outpatient Payment Rates for 2012 | 61 | 1 |
| Major Challenges | 61 | 1 |
| New Nationwide Database to Set Healthcare Reimbursement Rates | 61 | 1 |
| First DataBank/Medi-Span Settlement and the Impact on AWP | 62 | 1 |
| Renewal of Medicaid Drug Payment Policy | 63 | 1 |
| Proposed Cuts in Medicare Part B Reimbursement | 63 | 1 |
| New Trend in Free Trade Agreements Could Affect Healthcare Programs | 63 | 1 |
| Pricing and Reimbursement in the US - Major Therapy Areas | 64 | 6 |
| Pricing and Reimbursement in Major Therapy Areas | 65 | 1 |
| Heart Diseases | 65 | 1 |
| Cancer | 65 | 1 |
| Respiratory Diseases | 65 | 1 |
| Cerebrovascular Diseases | 65 | 1 |
| Other Major Therapy Areas | 66 | 1 |
| Obesity | 66 | 1 |
| Tuberculosis | 66 | 1 |
| Rheumatoid Arthritis (RA) | 66 | 1 |
| Orphan Diseases | 67 | 1 |
| Case Studies | 68 | 1 |
| Provenge under Medicare Coverage | 68 | 1 |
| AstraZeneca Ensures Reimbursement of Brilinta | 68 | 1 |
| Financial Assistance for Orphan Drug Letairis | 69 | 1 |
| Coverage for Biologic Product Enbrel | 69 | 1 |
| Pricing and Reimbursement in the US - Appendix | 70 | 6 |
| Market Definitions | 70 | 1 |
| Abbreviations | 70 | 2 |
| Research Methodology | 72 | 3 |
| Healthcare System | 73 | 1 |
| Methodology | 73 | 1 |
| Sources of Coverage | 73 | 1 |
| Pharmaceutical Regulations | 73 | 1 |
| Methodology | 73 | 1 |
| Sources of Coverage | 73 | 1 |
| Pricing of Pharmaceutical Drugs | 73 | 1 |
| Methodology | 73 | 1 |
| Sources of Coverage | 73 | 1 |
| Reimbursement of Pharmaceutical Drugs | 73 | 1 |
| Methodology | 73 | 1 |
| Sources of Coverage | 73 | 1 |
| Pricing and Reimbursement in Major Therapy Areas | 74 | 1 |
| Methodology | 74 | 1 |
| Sources of Coverage | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 74 | 1 |
| Sources | 74 | 2 |